|
|
Article: Early-Phase Data Show Prasugrel Demonstrates More Consistent Platelet Inhibition Compared to Clopidogrel.
- Article from:
- PR Newswire
- Article date:
- October 17, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
INDIANAPOLIS, Ind., and TOKYO, Japan, Oct. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company and Sankyo Co., Ltd. announced today data results from three early-phase, cross-over studies demonstrating that all subjects responded to prasugrel, an investigational antiplatelet agent, while 22 to 43 percent of the same subjects did not respond to clopidogrel (Plavix(R)), as measured by objectively defined parameters for inhibition of platelet aggregation. The data were presented at the Cardiovascular Research Foundation's (CRF) 17th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C.
"We are very encouraged by the ...